The present invention relates generally to infusion sets, including a disposable inserter for an infusion set, which ensures proper positioning of insertion by using an adhesive to hold an infusion set in position, and a ballistic inserter releasably coupled with the infusion set to insert a needle at a controlled rate of speed to a desired intradermal depth.
A large number of people, including those suffering from conditions such as diabetes use some form of infusion therapy, such as daily insulin infusions to maintain close control of their glucose levels. There are two principal modes of daily insulin therapy. The first mode includes syringes and insulin pens. These devices are simple to use and are relatively low in cost, but they require a needle stick at each injection, typically three to four times per day. The second mode includes infusion pump therapy, which entails the purchase of an insulin pump that lasts for about three years. The initial cost of the pump can be significant, but from a user perspective, the overwhelming majority of patients who have used pumps prefer to remain with pumps for the rest of their lives. This is because infusion pumps, although more complex than syringes and pens, offer the advantages of continuous infusion of insulin, precision dosing and programmable delivery schedules. This results in closer blood glucose control and an improved feeling of wellness.
The use of an infusion pump requires the use of a disposable component, typically referred to as an infusion set or pump set, which conveys the insulin from a reservoir within the pump into the skin of the user. An infusion set typically consists of a pump connector, a length of tubing, and a hub or base from which an infusion needle or cannula extends. The hub or base has an adhesive which retains the base on the skin surface during use, which may be applied to the skin manually or with the aid of a manual or automatic insertion device.
Currently, most insulin infusion sets deliver insulin to the sub-cutaneous layers of skin using either fixed metal needles or flexible plastic cannulas. Such infusion sets typically deliver insulin 4-10 mm below the skin surface. However, the upper 3 mm of skin surface, the intradermal space, facilitates better drug absorption. Unfortunately, due to the relative thinness of the intradermal layer, inserting a needle at such depth and maintaining an infusion site over an extended period of time within this narrow band is difficult.
Further, most insulin infusion sets typically do not provide any features to isolate the inserted needle from shock or other external forces. Since these infusion sets typically deliver insulin 4-10 mm below the skin surface, shock or other external forces to the set have less effect on the deeper inserted needle. However, where an attempt is made to target the upper 3 mm of skin surface, any shock or movement of the set can adversely affect needle insertion and infusion performance.
Still further, most insulin sets have inserters that can result in skin surface “tenting” during needle insertion, where the skin surface is deflected somewhat prior to or during needle insertion which makes precisely targeting the upper 3 mm of skin surface difficult.
Accordingly, a need exists for an infusion set that can deliver content to the upper 3 mm of skin surface, the intradermal space, to facilitate better drug absorption, while maintaining a degree of comfort to the user.
An object of the present invention is to provide an infusion set which can deliver insulin or other medicament to the upper 3 mm of skin surface, the intradermal space, to facilitate better drug absorption, while maintaining a degree of comfort to the user.
Another object of the present invention is to provide an infusion set having a disposable inserter that can insert a needle at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface.
Another object of the present invention is to provide an infusion set having a disposable inserter that can insert a needle at a controlled high rate of speed to substantially reduce tenting of the skin surface and insert a needle at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface.
Another object of the present invention is to provide an infusion set having a disposable inserter that can be removed, thereby leaving a low-profile infusion set at the infusion site.
Another object of the present invention is to provide an infusion set having a skin securing, adhesive layer to secure the skin surface at the insertion site such that the inserter that can insert a needle without a risk of tenting of the skin surface.
Another object of the present invention is to provide an infusion set that can isolate an inserted needle from external forces such that the needle can be maintained at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface during normal use.
These and other objects are substantially achieved by providing an infusion set having a disposable inserter that can insert a needle at a controlled high rate of speed to a depth to deliver insulin or other medicament to the upper 3 mm of skin surface, and a skin-securing adhesive layer to secure the skin surface at the insertion site such that the inserter that can insert a needle without a risk of tenting of the skin surface. The disposable inserter can be removed, thereby leaving a low-profile infusion set at the infusion site. The position of the inserted needle can be maintained by providing an inner and outer hub of the infusion set that can isolate the inserted needle from external forces such that the needle can be maintained at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface during normal use.
The various objects, advantages and novel features of the exemplary embodiments of the present invention will be more readily appreciated from the following detailed description when read in conjunction with the appended drawings, in which:
Throughout the drawings, like reference numerals will be understood to refer to like parts, components and structures.
The exemplary embodiments of the present invention deliver insulin or other medicament to the intradermal layers of the skin via a standard insulin pump or other similar device. By utilizing a disposable ballistic inserter, a skin securing adhesive, and an isolated inner hub, proper insertion and maintenance of the inserted needle in the intradermal space is ensured using a low profile set, while maintaining a degree of comfort to the user.
The exemplary embodiments of the present invention provide an exemplary infusion set having a disposable ballistic inserter that can insert a needle at a depth to deliver content to the upper 3 mm of skin surface. To do so, the exemplary embodiments comprise a disposable ballistic inserter that can insert a needle of an infusion set at a controlled high rate of speed to substantially reduce tenting of the skin surface and insert the needle at a depth to deliver insulin or other medicament to the upper 3 mm of skin surface. The disposable ballistic inserter can be removed, thereby leaving a low-profile infusion set at the infusion site. The infusion set is also provided with at least one skin securing, adhesive layer to secure the infusion set to the skin surface at the insertion site, such that the ballistic inserter when activated by the user is at the correct position relative to the skin surface, and such that the skin is secured during insertion to further aid needle insertion without a risk of tenting of the skin surface. The infusion set is still further provided with an inner and outer hub that can isolate an inserted needle from external forces such that the needle can be maintained at a depth to deliver content to the upper 3 mm of skin surface during normal use.
As shown in
As shown in greater detail in
As further shown in
The outer hub 102 still further comprises a stepped rail 122 around an outer circumference for releasably securing the ballistic inserter 200 to the infusion set 100. The stepped rail 122 is provided as a guidance feature to align travel in the normal direction after impact. Further, the stepped rail 122 comprises chamfers that are configured to allow the lower inserter housing 204 to be rotated clockwise as described in greater detail below. Rotating the lower inserter housing 204 causes attachment arms of the lower inserter housing 204 to flex out, thereby allowing the ballistic inserter 200 to be removed from the infusion set 100.
Returning to
The button 202 captures the spring 210 between a closed upper button surface within member 218 and the hammer 208. In doing so, the spring 210 is configured to urge the hammer 208 downward upon loading and release of the hammer. However, prior to activation, the hammer 208 is held from downward movement by one or more aims 214 and inclined detents 216 thereon, held by an opening in the lower inserter housing 204.
Accordingly, downward movement of the button 202 serves to first compress the spring 210. At or near an end of downward travel of the button 202, member 218 of the button 202 contact the inclined detents 216 of the hammer 208, which releases the one or more arms 214 and inclined detents 216 from the opening in the lower inserter housing 204 and the hammer 208 is released and urged downward by the spring 210. The button 202 is then locked to the lower inserter housing 204 at this point via button snaps 203 capturing detents on the lower inserter housing 204 as shown in
Once released by the button 202, the hammer 208 is urged downward and strikes the table 212. The struck table 212 now moves downward and the arms 220 of the table 212 extending through the outer hub 102 moves the inner hub 104 and needle 108 downward such that the inner hub 104 is placed at the infusion site, secured via adhesive 112, and needle 108 is inserted. In doing so, the inner hub 104 and needle 108 are driven into the skin surface at a controlled high rate of speed, of 3.3 ft/sec. (1.0 m/sec.) up to and including those greater than 10 ft/sec. (3.0 m/sec.), which minimizes the risk of tenting at needle insertion. By using such a driving spring, a high-speed insertion is achieved which is considered more reliable for insertion of short (i.e., 1.5 mm) needle or cannula.
As noted above, precise insertion is achieved by first securing the infusion set 100 to the infusion site via the adhesive 110, which permits the user to activate the disposable ballistic inserter 200 at the proper alignment as described above, and insert the needle. In doing so, the needle is driven into the skin surface at a controlled high rate of speed to minimize the risk of tenting at needle insertion. Further, the adhesive 110 at or very near the insertion site secures the skin surface and further minimizes tenting of the skin surface during insertion.
After insertion, the user can then turn or twist the ballistic inserter 200 relative to the secured infusion set 100 for release. Specifically, the infusion set 100 is secured to the infusion site via the adhesive 110 and 112, which permits the user to turn the ballistic inserter 200 relative to the set 100 for release without affecting infusion set position, such that the rail 122 and openings 118 and 120 of the outer hub 102 allow the release and removal of the disposable ballistic inserter 200. Specifically, the arms 220 of the table member 212 of the ballistic inserter 200 pass through the outer hub 102 and contact and secure the inner hub 104. The table 212 is releasably locked to the inner hub 104 via arms 220 which protrude through openings 118 of the outer hub 102, and capture detents 222 on an upper surface of the inner hub 104. The arms 220 of the table 212 can be released from the detents 222 of the inner hub 104 by a twisting motion. The arcuate form of the openings 118 allow rotation of the arms 220 of the table 212, and gaps 120 in the openings 118 permit the arms 220 of the table 212 to be pulled free from the outer hub 102 of the infusion set 100. Further, rotating the lower inserter housing 204 causes attachment anus of the lower inserter housing 204 to flex out, thereby allowing the ballistic inserter 200 to be removed from the infusion set 100.
In an exemplary use of the embodiments of the present invention, proper insertion of the infusion set 100 into the delivery site consists of three straightforward steps. First, the infusion set 100 and ballistic inserter 200 are positioned and used to insert the needle 108 into the intradermal layers of the skin. To do so, an adhesive covering backing (not shown) if provided, can be peeled off one or both of the skin adhesive layers 110 and 112 of the infusion set 100, and the infusion set 100 is adhered to the skin surface in the area of the desired infusion site. The user then presses downward on the inserter button 202, loading the spring 208, releasing the hammer 208 to strike the table 212, which moves the inner hub 104, placing the inner hub 104 of the infusion set at the infusion site and inserting the needle 108 into the skin surface of the infusion site.
Second, the ballistic inserter 200 is removed from the infusion set 100 with a twisting motion and then discarded, leaving the low-profile infusion set 100 in place. As shown in
As shown in
The user can prime the pump tube attachment 224 prior to attachment to the infusion set 100, and then deliver insulin or other medicament to the infusion site via the attached infusion pump (not shown).
Inside the exemplary device, the inner hub 104 is entirely contained within the outer hub 102, and the ballistic inserter 200 can be connected to the inner hub 104 through openings in the outer hub 102. As noted above, the ballistic inserter 200 comprises the button 202, spring 210, hammer 208 and table 212. Accordingly, as the user presses downward on the inserter button 202, the spring 210 is loaded up against the hammer 208, which is snapped to the lower inserter housing 204. When the spring 210 is fully compressed, the same downward motion unlatches the hammer snaps of arms 214, and the button 202 is locked into the lower inserter housing 204.
The spring 210 is compressed until it gains a maximum potential energy. This energy is determined by calculating the torsional stresses built up in the spring as it is compressed. By calculating potential energy, and the kinetic energy at the point of needle insertion, an insertion velocity can be calculated. In an exemplary embodiment of the present invention, the spring 210 is configured to insert an exemplary needle at a controlled high rate of speed, of 3.3 ft/sec. (1.0 m/sec.) up to and including those greater than 10 ft/sec. (3.0 m/sec.). Depending upon cannula sharpness, a high terminal velocity produces more reliable results for intradermal insertions of short (i.e., 1.5 mm) needle or cannula.
When the hammer snaps of arms 214 are unlatched, the hammer 208 is propelled downward by the spring 210 toward the table 212. The table 212 is releasably locked to the inner hub 104 via one or more arms 220 which protrude through the outer hub 102. When the hammer 208 collides with the table 212, the inner hub 104 moves downward, adheres to the skin surface, and pierces the skin surface with the needle 108.
Prior to insertion, the table 212 prevents rotation of the ballistic inserter 200 with respect to the outer hub 102.
After the needle 108 is inserted, and the table 212 and inner hub 104 are in a down position, the user can turn the ballistic inserter 200 (e.g., clockwise), and the table 212 rotationally slides away from the inner hub 104 which is locked to the skin surface via the adhesive layer 112. This turning motion also flexes the lower inserter housing 204 snaps 205 outward, away from the outer hub 102. As described above and shown in
Accordingly, a simple rotational and vertical motion can be used to release the ballistic inserter 200. Potentially, a rotational unlocking motion can cause an infusion set to peel off the skin surface if the user twists the entire assembly at an angle. Disconnecting the ballistic inserter 200 from the outer hub 102 after the down stroke of the button 202 minimizes this risk, and is more ergonomic and reliable.
To ensure shock isolation of the inner hub 104, the inner hub 104 is fully enclosed by the outer hub 102, and is connected to the outer hub 102 solely through the flexible tubing 116 after removal of the ballistic inserter 200. Further, the inner hub is adhesively secured to the skin surface using the adhesive layer 112 that is separate from the adhesive layer 110 securing the outer hub 102 to the skin surface. The inner hub 104 has a separate adhesive, and is connected to the outer hub 102 via only the flexible tube 116, such that the inner hub 104 is protected from external vibrations and forces. In the exemplary embodiment shown, the flexible tubing 116 at least partially loops upward (on the vertical) between the inner hub 104 and the outer hub 102, which permits a smaller footprint device profile. As noted above, the inner hub 104 is connected to the outer hub 102 solely through the flexible tubing 116. Prior to insertion, the inner hub 104 is held within the outer hub 102 by the table 212. After activation and release and removal of the table 212, the inner hub 104 is held in place by the inner skin adhesive 112 beneath the inner hub 104, and is connected to the outer hub 102 through the flexible tubing 116. The tube set connection 224 can then be snapped over the same features which held the ballistic inserter 200, and rotated to allow for comfortable pump tube routing.
In the disclosed arrangement, the needle 108 is protected from external forces and vibrations by the outer hub 102, and the isolation of the inner hub 104. By carefully isolating the inner hub 104 and the needle 108 from external forces, the needle position within the intradermal layer is maintained.
Further, the arrangement of the assembled set 100 and ballistic inserter 200 ensure proper alignment and positioning. Most existing inserters are either oversized, to ensure an insertion force perpendicular to the skin surface, or are thin and portable, which can lead to misaligned insertion. In the exemplary embodiments of the present invention, by first adhering or “locking” the outer skin adhesive 110 of the infusion set 100 to the skin surface, the ballistic inserter 200 is aligned properly for needle insertion. Accordingly, the exemplary embodiments of the present invention can include a relatively small inserter which is properly aligned with the infusion site at a time of use.
Such a system and method further allows the use of a small intradermal needle, or microneedle, which can be placed perpendicular to the skin surface, and which is isolated from outside forces, thereby maintaining position and causing less pain to the user during use. Still further, by infusing into the intradermal layer of the skin, the exemplary embodiments of the present invention offer the potential for better absorption of insulin when compared to subcutaneous delivery systems. In doing so, it may be possible for the typical user to both consume less insulin and maintain a better medicament regime. It will be appreciated that multiple needles or microneedles can be used, if desired, in place of a single needle or microneedle.
As noted above, intradermal infusion sets are at risk of tenting, which is the undesired effect where skin is deflected at or during insertion, creating a shape associated with a tent. In doing so, the skin surface tents during needle insertion rather than needle penetration into the skin. However, since the present invention provides a needle which is inserted at a controlled high rate of speed, of 3.3 ft/sec. (1.0 m/sec.) up to and including those greater than 10 ft/sec., and wherein the skin surface is secured at and/or near the insertion site, the exemplary embodiments of the present invention do not present such a risk and ensure more precise needle insertion depth.
In existing steel cannula infusion sets which deliver insulin to the subcutaneous layer, the needle is not isolated from any undesired outside forces which may cause pain when translated to the needle and the needle moves within the skin. Also, other intradermal devices face problems of premature or otherwise undesired needle removal when the device is bumped if the needle is not isolated form the outside forces.
In the exemplary embodiments of the present invention, the intradermal needle is isolated from outside forces by at least three features. First, the outer hub 102 shields the sensitive inner hub 104 from direct contact with external forces. Second, the inner hub 104 and outer hub 102 are secured to the infusion site via separate adhesive segments. Third, the connection between the outer hub 102 and the inner hub 104 is extremely flexible, so that any forces imparted on the protective outer hub 102 do not carry over to the needle 108. For example, the provision of the flexible tubing connection 116, along with the outer hub 102, serves to effectively isolate the needle 108 from the outside forces and other interference.
Proper inserter alignment is accomplished by providing a solid, fixed foundation for the user to press the inserter button. Such a solid, fixed foundation is provided by the surrounding member 106, outer skin adhesive 110, and the inner skin adhesive 112 The skin adhesive layers secure the set 100 at a desired orientation, such that the attached ballistic inserter 200 is also at a desired orientation of use, and the user is substantially prevented from holding the inserter at angles to the insertion site. Accordingly, precise, repeatable insertions are accomplished via the pre-adhesion of the outer hub 102. By fixing a ring of skin around the actual insertion site, movement of the skin surface relative to the inner hub are reduced.
Existing infusion sets sometimes require the use of a separate inserter. In the exemplary embodiments of the present invention described herein, the user does not have to carry a separate inserter or load the infusion set onto an inserter. The integrated system allows the user more freedom from carrying and loading a separate inserter resulting in improved convenience and simpler operation.
Although only a few exemplary embodiments of the present invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the appended claims and their equivalents.
This application claims the benefit under 35 U.S.C. §119(e) of a U.S. provisional patent application of Cole Constantineau et al. entitled “Ballistic Microneedle Infusion Device”, Ser. No. 61/344,970, filed on Nov. 30, 2010, the entire content of said application being incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3857382 | Williams, Jr. et al. | Dec 1974 | A |
3918355 | Weber | Nov 1975 | A |
3963380 | Thomas, Jr. et al. | Jun 1976 | A |
4204538 | Cannon | May 1980 | A |
4490141 | Lacko et al. | Dec 1984 | A |
4685902 | Edwards et al. | Aug 1987 | A |
4723947 | Konopka | Feb 1988 | A |
4734092 | Millerd | Mar 1988 | A |
4755173 | Konopka et al. | Jul 1988 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5226899 | Lee et al. | Jul 1993 | A |
5242406 | Gross et al. | Sep 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5453099 | Lee et al. | Sep 1995 | A |
5522803 | Teissen-Simony | Jun 1996 | A |
5536249 | Castellano et al. | Jul 1996 | A |
5545143 | Fischell | Aug 1996 | A |
5545152 | Funderburk et al. | Aug 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5728074 | Castellano et al. | Mar 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5820602 | Kovelman et al. | Oct 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5858005 | Kriesel | Jan 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5957895 | Sage et al. | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5980506 | Mathiasen | Nov 1999 | A |
6017328 | Fischell et al. | Jan 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6068615 | Brown et al. | May 2000 | A |
6074369 | Sage et al. | Jun 2000 | A |
6086575 | Mejslov | Jul 2000 | A |
6093172 | Funderburk et al. | Jul 2000 | A |
6110148 | Brown et al. | Aug 2000 | A |
6123690 | Mejslov | Sep 2000 | A |
6132400 | Waldenburg | Oct 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6206134 | Stark et al. | Mar 2001 | B1 |
6254586 | Mann et al. | Jul 2001 | B1 |
6272364 | Kurnik | Aug 2001 | B1 |
6275717 | Gross et al. | Aug 2001 | B1 |
6277627 | Hellinga | Aug 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6302866 | Marggi | Oct 2001 | B1 |
6352523 | Brown et al. | Mar 2002 | B1 |
6355021 | Nielsen et al. | Mar 2002 | B1 |
6391005 | Lum et al. | May 2002 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6520938 | Funderburk et al. | Feb 2003 | B1 |
6521446 | Hellinga | Feb 2003 | B2 |
6544212 | Galley et al. | Apr 2003 | B2 |
6546269 | Kurnik | Apr 2003 | B1 |
6551276 | Mann et al. | Apr 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6576430 | Hsieh et al. | Jun 2003 | B1 |
6579267 | Lynch et al. | Jun 2003 | B2 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6607509 | Bobroff et al. | Aug 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6692457 | Flaherty | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6706159 | Moerman et al. | Mar 2004 | B2 |
6723072 | Mahoney et al. | Apr 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6749560 | Konstorum et al. | Jun 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6830558 | Flaherty et al. | Dec 2004 | B2 |
6830562 | Mogensen et al. | Dec 2004 | B2 |
6840922 | Nielsen et al. | Jan 2005 | B2 |
6852104 | Blomquist | Feb 2005 | B2 |
6890319 | Crocker | May 2005 | B1 |
6949084 | Marggi et al. | Sep 2005 | B2 |
6960162 | Saadat et al. | Nov 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6977180 | Hellinga et al. | Dec 2005 | B2 |
6997907 | Safabash et al. | Feb 2006 | B2 |
7004928 | Aceti et al. | Feb 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7052251 | Nason et al. | May 2006 | B2 |
7056302 | Douglas | Jun 2006 | B2 |
7064103 | Pitner et al. | Jun 2006 | B2 |
7070580 | Nielsen | Jul 2006 | B2 |
7083597 | Lynch et al. | Aug 2006 | B2 |
7109878 | Mann et al. | Sep 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7137964 | Flaherty | Nov 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7207974 | Safabash et al. | Apr 2007 | B2 |
7214207 | Lynch et al. | May 2007 | B2 |
7226278 | Nason et al. | Jun 2007 | B2 |
7303543 | Maule et al. | Dec 2007 | B1 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7310544 | Brister et al. | Dec 2007 | B2 |
7318816 | Bobroff et al. | Jan 2008 | B2 |
7329239 | Safabash et al. | Feb 2008 | B2 |
7354420 | Steil et al. | Apr 2008 | B2 |
7407493 | Cane′ | Aug 2008 | B2 |
7496392 | Alarcon et al. | Feb 2009 | B2 |
7585287 | Bresina et al. | Sep 2009 | B2 |
7699807 | Faust et al. | Apr 2010 | B2 |
7713258 | Adams et al. | May 2010 | B2 |
7722595 | Pettis et al. | May 2010 | B2 |
7731691 | Cote et al. | Jun 2010 | B2 |
7736338 | Kavazov et al. | Jun 2010 | B2 |
7879010 | Hunn et al. | Feb 2011 | B2 |
7896844 | Thalmann et al. | Mar 2011 | B2 |
8152769 | Douglas et al. | Apr 2012 | B2 |
8152771 | Mogensen et al. | Apr 2012 | B2 |
8162892 | Mogensen et al. | Apr 2012 | B2 |
8172803 | Morrissey et al. | May 2012 | B2 |
8172805 | Mogensen et al. | May 2012 | B2 |
8221359 | Kristensen et al. | Jul 2012 | B2 |
8262618 | Scheurer | Sep 2012 | B2 |
8277415 | Mounce et al. | Oct 2012 | B2 |
8285328 | Caffey et al. | Oct 2012 | B2 |
8287467 | List et al. | Oct 2012 | B2 |
8287516 | Kornerup et al. | Oct 2012 | B2 |
8306596 | Schurman et al. | Nov 2012 | B2 |
8310415 | Mclaughlin et al. | Nov 2012 | B2 |
8313468 | Geipel et al. | Nov 2012 | B2 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20030055380 | Flaherty | Mar 2003 | A1 |
20030109829 | Mogensen et al. | Jun 2003 | A1 |
20030176852 | Lynch et al. | Sep 2003 | A1 |
20030199823 | Bobroff et al. | Oct 2003 | A1 |
20040002682 | Kovelman et al. | Jan 2004 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040044306 | Lynch et al. | Mar 2004 | A1 |
20040059316 | Smedegaard | Mar 2004 | A1 |
20040078028 | Flaherty et al. | Apr 2004 | A1 |
20040092865 | Flaherty et al. | May 2004 | A1 |
20040092878 | Flaherty | May 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127844 | Flaherty | Jul 2004 | A1 |
20040153032 | Garribotto et al. | Aug 2004 | A1 |
20040158207 | Hunn et al. | Aug 2004 | A1 |
20040162521 | Bengtsson | Aug 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040204687 | Mogensen et al. | Oct 2004 | A1 |
20040220551 | Flaherty et al. | Nov 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050021005 | Flaherty et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050043687 | Mogensen et al. | Feb 2005 | A1 |
20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
20050090784 | Nielsen et al. | Apr 2005 | A1 |
20050101912 | Faust et al. | May 2005 | A1 |
20050101932 | Cote et al. | May 2005 | A1 |
20050101933 | Marrs et al. | May 2005 | A1 |
20050113761 | Faust et al. | May 2005 | A1 |
20050124936 | Mogensen et al. | Jun 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050182366 | Vogt et al. | Aug 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050215982 | Malave et al. | Sep 2005 | A1 |
20050222645 | Malave et al. | Oct 2005 | A1 |
20050238507 | DiIanni et al. | Oct 2005 | A1 |
20050245799 | Brauker et al. | Nov 2005 | A1 |
20050273076 | Beasley et al. | Dec 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060001551 | Kraft et al. | Jan 2006 | A1 |
20060041229 | Garibotto et al. | Feb 2006 | A1 |
20060074381 | Malave et al. | Apr 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060129090 | Moberg et al. | Jun 2006 | A1 |
20060135913 | Ethelfeld | Jun 2006 | A1 |
20060142698 | Ethelfeld | Jun 2006 | A1 |
20060173410 | Moberg et al. | Aug 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060200073 | Radmer et al. | Sep 2006 | A1 |
20060217663 | Douglas | Sep 2006 | A1 |
20060263839 | Ward et al. | Nov 2006 | A1 |
20060264835 | Nielsen et al. | Nov 2006 | A1 |
20060282290 | Flaherty et al. | Dec 2006 | A1 |
20070016149 | Hunn et al. | Jan 2007 | A1 |
20070021733 | Hansen et al. | Jan 2007 | A1 |
20070027427 | Trautman et al. | Feb 2007 | A1 |
20070049865 | Radmer et al. | Mar 2007 | A1 |
20070073229 | Gorman et al. | Mar 2007 | A1 |
20070073559 | Stangel | Mar 2007 | A1 |
20070088244 | Miller et al. | Apr 2007 | A1 |
20070088271 | Richards | Apr 2007 | A1 |
20070093754 | Mogensen et al. | Apr 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070149925 | Edwards et al. | Jun 2007 | A1 |
20070191702 | Yodfat et al. | Aug 2007 | A1 |
20070219496 | Kamen et al. | Sep 2007 | A1 |
20080004515 | Jennewine | Jan 2008 | A1 |
20080021395 | Yodfat et al. | Jan 2008 | A1 |
20080051697 | Mounce et al. | Feb 2008 | A1 |
20080051698 | Mounce et al. | Feb 2008 | A1 |
20080051709 | Mounce et al. | Feb 2008 | A1 |
20080051710 | Moberg et al. | Feb 2008 | A1 |
20080051711 | Mounce et al. | Feb 2008 | A1 |
20080051714 | Moberg et al. | Feb 2008 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20080051718 | Kavazov et al. | Feb 2008 | A1 |
20080051727 | Moberg et al. | Feb 2008 | A1 |
20080051730 | Bikovsky | Feb 2008 | A1 |
20080051738 | Griffin | Feb 2008 | A1 |
20080051765 | Mounce | Feb 2008 | A1 |
20080097321 | Mounce et al. | Apr 2008 | A1 |
20080097326 | Moberg et al. | Apr 2008 | A1 |
20080097327 | Bente et al. | Apr 2008 | A1 |
20080097328 | Moberg et al. | Apr 2008 | A1 |
20080097375 | Bikovsky | Apr 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080103483 | Johnson et al. | May 2008 | A1 |
20080116647 | Anderson et al. | May 2008 | A1 |
20080119707 | Stafford | May 2008 | A1 |
20080132842 | Flaherty | Jun 2008 | A1 |
20080147041 | Kristensen | Jun 2008 | A1 |
20080160492 | Campbell et al. | Jul 2008 | A1 |
20080194924 | Valk et al. | Aug 2008 | A1 |
20080215006 | Thorkild | Sep 2008 | A1 |
20080261255 | Tolosa et al. | Oct 2008 | A1 |
20080264261 | Kavazov et al. | Oct 2008 | A1 |
20080269680 | Ibranyan et al. | Oct 2008 | A1 |
20080269713 | Kavazov | Oct 2008 | A1 |
20080281297 | Pesach et al. | Nov 2008 | A1 |
20080294028 | Brown | Nov 2008 | A1 |
20080306434 | Dobbles et al. | Dec 2008 | A1 |
20080312608 | Christoffersen et al. | Dec 2008 | A1 |
20080319414 | Yodfat et al. | Dec 2008 | A1 |
20090005724 | Regittnig et al. | Jan 2009 | A1 |
20090005728 | Weinert et al. | Jan 2009 | A1 |
20090012472 | Ahm et al. | Jan 2009 | A1 |
20090062767 | Van Antwerp et al. | Mar 2009 | A1 |
20090076453 | Mejlhede et al. | Mar 2009 | A1 |
20090124979 | Raymond et al. | May 2009 | A1 |
20090198191 | Chong et al. | Aug 2009 | A1 |
20090198215 | Chong et al. | Aug 2009 | A1 |
20090204077 | Hasted et al. | Aug 2009 | A1 |
20090221971 | Mejlhede et al. | Sep 2009 | A1 |
20090240240 | Hines et al. | Sep 2009 | A1 |
20090254041 | Krag et al. | Oct 2009 | A1 |
20090281497 | Kamen et al. | Nov 2009 | A1 |
20090326457 | O'Connor | Dec 2009 | A1 |
20100049129 | Yokoi et al. | Feb 2010 | A1 |
20100160902 | Aeschilimann et al. | Jun 2010 | A1 |
20100217105 | Yodfat et al. | Aug 2010 | A1 |
20100222743 | Frederickson et al. | Sep 2010 | A1 |
20100286714 | Gyrn et al. | Nov 2010 | A1 |
20100291588 | Mcdevitt et al. | Nov 2010 | A1 |
20100298830 | Browne et al. | Nov 2010 | A1 |
20120253282 | Nagel et al. | Oct 2012 | A1 |
20120259185 | Yodfat et al. | Oct 2012 | A1 |
20120265034 | Wisniewski et al. | Oct 2012 | A1 |
20120277554 | Schurman et al. | Nov 2012 | A1 |
20120277667 | Yodat et al. | Nov 2012 | A1 |
20120277724 | Larsen et al. | Nov 2012 | A1 |
20120283540 | Brüggemann | Nov 2012 | A1 |
20120291778 | Nagel et al. | Nov 2012 | A1 |
20120293328 | Blomquist | Nov 2012 | A1 |
20120296269 | Blomquist | Nov 2012 | A1 |
20120296310 | Blomquist | Nov 2012 | A1 |
20120296311 | Brauker et al. | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
0 980 687 | Feb 2000 | EP |
1 743 667 | Jan 2007 | EP |
WO 99-34212 | Jul 1999 | WO |
WO 2007-051139 | May 2007 | WO |
WO 2008051920 | May 2008 | WO |
WO 2009-021039 | Feb 2009 | WO |
WO 2009-021052 | Feb 2009 | WO |
WO 2010085338 | Jul 2010 | WO |
Number | Date | Country | |
---|---|---|---|
20120143136 A1 | Jun 2012 | US |
Number | Date | Country | |
---|---|---|---|
61344970 | Nov 2010 | US |